EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Utility and prognostic value of diagnosing MAFLD in patients undergoing liver transplantation for alcohol‐related liver disease

Benedict T K Vanlerberghe iD, Hannah van Malenstein, Mauricio Sainz-Bariga, Ina Jochmans, David Cassiman, Diethard Monbaliu, Schalk van der Merwe, Jacques Pirenne, Frederik Nevens, Jef Verbeek

Clinical Transplantation · 2023

DOI: 10.1111/ctr.14965 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Transplantation, 2023. Verfasst von Benedict T K Vanlerberghe und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Liver Transplantation, Diabetes Mellitus, Type 2, Liver Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recently, the term metabolic dysfunction‐associated fatty liver disease (MAFLD) was proposed to replace non‐alcoholic fatty liver disease (NAFLD). This concept enables diagnosing liver disease associated with metabolic dysfunction in patients with alcohol‐related liver disease (ALD), a main indication for liver transplantation (LTx). We assessed MAFLD prevalence in ALD patients undergoing LTx and its prognostic value on post‐LTx outcomes.

Methods

We retrospectively analyzed all ALD patients transplanted at our center between 1990 and August 2020. MAFLD was diagnosed based on the presence or history of hepatic steatosis and a BMI > 25 or type II diabetes or ≥ 2 metabolic risk abnormalities at LTx. Overall survival and risk factors for recurrent liver and cardiovascular events were analyzed by Cox regression.

Results

Of the 371 included patients transplanted for ALD, 255 (68.7%) had concomitant MAFLD at LTx. Median follow‐up post‐LTx was 72 months (IQR: 34.50–122). Patients with ALD‐MAFLD were older at LTx ( p = .001), more often male ( p < .001) and more frequently had hepatocellular carcinoma ( p < .001). No differences in perioperative mortality and overall survival were found. ALD‐MAFLD patients had an increased risk of recurrent hepatic steatosis, irrespective of alcohol relapse, but no superimposed risk of cardiovascular events.

Conclusions

The co‐presence of MAFLD at LTx for ALD is associated with a distinct patient profile and is an independent risk factor for recurrent hepatic steatosis. The use of MAFLD criteria in ALD patients might increase awareness and treatment of specific hepatic and systemic metabolic abnormalities before and after LTx.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseLiver TransplantationDiabetes Mellitus, Type 2Liver NeoplasmsCardiovascular DiseasesHumansMalePrognosisRetrospective StudiesNeoplasm Recurrence, Local

Stichwörter der Autor:innen

alcohol-related liver diseaseliver transplantationmetabolic-dysfunction related liver disease

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
  • Laboratory of Hepatology, Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium.
  • Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, the Netherlands.
  • School of Nutrition and Translational Research in Metabolism (NUTRIM), University Maastricht, Maastricht, the Netherlands.
  • Transplantation Research Group, Department of Microbiology and Transplantation, Laboratory of Abdominal Transplantation, KU Leuven, University of Leuven, Leuven, Belgium.
  • Department of Abdominal Transplant Surgery, University Hospitals Leuven, Leuven, Belgium.

ORCID-Profile: Benedict T K Vanlerberghe

Zitieren

APA

Vanlerberghe, B. T. K., van Malenstein, H., Sainz-Bariga, M., Jochmans, I., Cassiman, D., Monbaliu, D., van der Merwe, S., Pirenne, J., Nevens, F., & Verbeek, J. (2023). Utility and prognostic value of diagnosing MAFLD in patients undergoing liver transplantation for alcohol‐related liver disease. Clinical Transplantation. https://doi.org/10.1111/ctr.14965

Vancouver

Vanlerberghe BTK, van Malenstein H, Sainz-Bariga M, Jochmans I, Cassiman D, Monbaliu D, et al. Utility and prognostic value of diagnosing MAFLD in patients undergoing liver transplantation for alcohol‐related liver disease. Clinical Transplantation. 2023. doi:10.1111/ctr.14965

BibTeX
@article{Vanlerberghe2023,
  author = {Vanlerberghe, Benedict T K and van Malenstein, Hannah and Sainz-Bariga, Mauricio and Jochmans, Ina and Cassiman, David and Monbaliu, Diethard and van der Merwe, Schalk and Pirenne, Jacques and Nevens, Frederik and Verbeek, Jef},
  title = {Utility and prognostic value of diagnosing MAFLD in patients undergoing liver transplantation for alcohol‐related liver disease},
  journal = {Clinical Transplantation},
  year = {2023},
  doi = {10.1111/ctr.14965}
}
Kostenlos starten →